1 / 25

Richard E. Chaisson, MD Center for Tuberculosis Research Johns Hopkins University

TB/HIV Research Priorities and Recent Developments. Richard E. Chaisson, MD Center for Tuberculosis Research Johns Hopkins University. Examples of Research Needed. Basic –immunology, molecular biology, genomics, drug discovery Translational – pathogenesis

danil
Télécharger la présentation

Richard E. Chaisson, MD Center for Tuberculosis Research Johns Hopkins University

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TB/HIV Research Priorities and Recent Developments Richard E. Chaisson, MD Center for Tuberculosis Research Johns Hopkins University

  2. Examples of Research Needed • Basic –immunology, molecular biology, genomics, drug discovery • Translational – pathogenesis • Clinical – observational, trials, outcomes • Public Health – intervention paradigms • Operational – functional strategies • Health Services – health system structure • Cost-effectiveness – impact on DALYs • Behavioral – health seeking behavior, delays, clinician behavior

  3. So many questions, so little time… • Epidemiology of TB/HIV • Diagnosis of latent and active TB • TB/HIV clinical issues • Treatment of TB in setting of HIV • ART, drug interactions and MDR • IRIS • New drugs • Preventive therapy • Public health interventions

  4. So many questions, so little time… • Epidemiology of TB/HIV • Diagnosis of latent and active TB • TB/HIV clinical issues • Treatment of TB in setting of HIV • ART, drug interactions and MDR • IRIS • New drugs • Preventive therapy • Public health interventions

  5. Community TB Prevalence in Masipumelela, South Africa Bekker et al., CROI 2006

  6. So many questions, so little time… • Epidemiology of TB/HIV • Diagnosis of latent and active TB • TB/HIV clinical issues • Treatment of TB in setting of HIV • ART, drug interactions and MDR • IRIS • New drugs • Preventive therapy • Public health interventions

  7. Current Approaches to Diagnosing TB in Resource Poor Settings • Reliance on antiquated tools with poor sensitivity

  8. Diagnosis of Latent and Active TBOpportunities for Research • Latent TB • Interferon-gamma based assays • Proteomic-based antigen or antibody detection • Lateral flow and other platforms • Active TB • MGIT based diagnostics • Novel culture systems • Antigen detection in sputum • Automated nucleic acid amplification

  9. Clinical Markers for Confirming Smear Negative TB in HIV+ Patients in South Africa Cape Town Study, HIV+ • Follow up study in KZN • HIV+ and HIV- patients with suspected SNTB • Response to therapy monitored • Response to therapy at week 8 = 96% for TB patients D Wilson et al., Int J TB Lung Dis, 2006 D Wilson et al., WAC Toronto, Abstract MOPE0145

  10. Time to Positive Culture by MODS or L-J in 1639 Respiratory Specimens from TB Suspects in Brazil and Honduras MODS – Sm+ LJ – Sm+ Arias, Dorman et al., 2006

  11. So many questions, so little time… • Epidemiology of TB/HIV • Diagnosis of latent and active TB • TB/HIV clinical issues • Treatment of TB in setting of HIV • ART, drug interactions and MDR • IRIS • New drugs • Preventive therapy • Public health interventions

  12. Impact of an Opt-Out vs. Opt-In Strategy for HIV Testing of TB Patients in the Eastern Cape, South Africa: A Cluster Randomized Trial Pope et al., WAC Toronto, Abstract #THKC205

  13. So many questions, so little time… • Epidemiology of TB/HIV • Diagnosis of latent and active TB • TB/HIV clinical issues • Treatment of TB in setting of HIV • ART, drug interactions and MDR • IRIS • New drugs • Preventive therapy • Public health interventions

  14. ART, Drug Interactions and MDR TB • TB in patients on ART (Lawn et al., WAC Toronto, #MOPE 0175) • 944 patients initiating ART in Western Cape • 25% prevalent TB, 10% with new TB • TB incidence after ART 10.4 cases per 100 PY • MDR TB (Vargas et al., WAC Toronto, Abstract #WEPE0166) • 209 HIV+/TB patients in Lima • 34% MDR, 10% INH-resistant, median CD4 = 44 • XDR TB (Gandhi et al., WAC Toronto,#THLB0210) • Epidemic MDR and XDR TB in KZN, South Africa • All XDR TB patients HIV+, 51% with no prior treatment

  15. p =0.006 NS 4000 PPD 4000 CMV 3500 3500 3000 3000 2500 2500 PBMC PBMC 2000 2000 6 6 SFC/10 SFC/10 1500 1500 1000 1000 500 500 0 0 T BK M 0 T IRS M 3 M 6 T BK M 0 M1 M 3 M6 IRS+ n=9 (41%) IRS- n=13 DTH Responses Measured by Elispot in Patients with and without IRIS 22 HIV-TB co-infected patients prospectively followed after anti-mycobacterial (TBK) then ARV (M0) therapy initiation Bourgarit et al., AIDS. 2006;20:F1-7, CROI 2006

  16. TBTC Study 27: Moxifloxacin vs. Ethambutol as 4th Drug in Initial Treatment of Smear+ TB P=0.02 P=0.003 Median Time to Culture Conversion: Moxi 43 d vs. EMB 56 d (p=0.01) Burman et al., AJRCCM 2006;174:331-8

  17. TBTC Study 27Sputum culture conversion among key sub-groups Adjusted P 0.03 0.003 <0.0001 Culture conversion 66% (137/206) 84% ( 60/71) 66% ( 89/134) 76% (108/143) 63% (110/175) 85% ( 87/102) Cavitation No cavitation Age <31 years Age >31 years African North American Burman et al., AJRCCM 2006;174:331-8

  18. Moxifloxacin and PA-824 in a Murine TB Model R, rifampin; M, moxifloxacin; Z, pyrazinamide; Pa, PA-824. Nuermberger et al., Antimicrob Agents Chemother 2006;50:2621

  19. So many questions, so little time… • Epidemiology of TB/HIV • Diagnosis of latent and active TB • TB/HIV clinical issues • Treatment of TB in setting of HIV • ART, drug interactions and MDR • IRIS • New drugs • Preventive therapy • Public health interventions

  20. TB Incidence in Brazilian HIVPatients by Treatment Category Golub et al., WAC Toronto, Abstract MOPE0395

  21. Novel TB Preventive Regimens in HIV-Infected Adults in Soweto: PHRU/JHU Trial • Open label, randomized trial • HIV+/PPD+ adults not on HAART at enrollment • Active TB excluded (23% screen failures  TB+) • Regimens • Rifapentine 900 mg/INH 900 weekly for 12 weeks • Rifampin 600 mg/INH 600 mg twice weekly for 12 weeks • INH 300 mg daily continuously • INH 300 mg daily for 6 months • Endpoint – TB-free survival

  22. Probability of TB After Enrollment (All Treatment Groups)

  23. So many questions, so little time… • Epidemiology of TB/HIV • Diagnosis of latent and active TB • TB/HIV clinical issues • Treatment of TB in setting of HIV • ART, drug interactions and MDR • IRIS • New drugs • Preventive therapy • Public health interventions

  24. C R E A E

  25. Research in TB/HIV • The need is enormous • There are abundant opportunities to contribute • Interdisciplinary and novel approaches are needed • New paradigms must be developed • “The greatest obstacle to discovery is not ignorance - it is the illusion of knowledge.”--Daniel Boorstein

More Related